occasions. Carving a study's data into multiple pieces and publishing these similar pieces individually is known as 'salami slicing' or as publishing 'least publishable units' [1] [2] [3] [4] .
'Salami slicing' may distort the medical literature, making a drug appear as if it has greater support than it has actually garnered from empirical investigations. A reader who does not look closely may not notice that multiple publications regarding a drug's efficacy and safety are actually based on the same underlying group of research participants. Salami manuscripts may waste the valuable time of peer reviewers. Journal editors from a variety of disciplines have bemoaned the practice of 'salami slicing' [1] [2] [3] [4] [5] [6] . In general, salami publications have been linked to the 'publish or perish' environment of academia; however, salami publications are likely used for more than just advancing the careers of academics.
Drug marketers have noted that journal publications are an important factor in drug sales. Putting it bluntly, one memo from Pfizer asked 'What is the purpose of publication?' and replied, in part 'High quality and timely publications optimize our ability to sell Zoloft most effectively' [ 7 , p. 18 ]. An internal Eli Lilly document listed 'new studies, publications, presentations …' under the heading of 'support the schizophrenia and bipolar franchises worldwide' for its antipsychotic drug olanzapine [ 8 , p. 3] . PeerView is a company which provides a variety of services to the drug industry, including '… products that support publication strategy and other commercialization processes for our pharmaceutical and biotech clients …' [9] . PeerView's CEO, Timothy Bacon, stated that '… most pharma and biotech companies recognize the significant impact that the clear and consistent publication of results will have on subsequent commercialization efforts …' [ 10 , p. 2] .
Salami publications may be included as part of a pharmaceutical firm's publication plan. When supportive and highly similar points about a drug's efficacy and/or safety from a single clinical trial are published in a variety of journals, a wide audience of potential prescribers and key opinion leaders is reached. Thus, in addition to padding the curricula vitae of researchers, salami publications may lead to the results of a successful trial being disseminated across several publications, likely helping to boost product visibility and reinforcing the product's key marketing messages. Because various researchers and clinicians read differing journals, they may not notice that redundant findings are being presented in multiple publications. Empirical research on the prevalence of salami publications is relatively sparse and has found quite disparate results [11] [12] [13] [14] . Most research on salami publications has focused on overlapping publications of individual clinical trials. Little attention has been placed on pooled analyses, publications in which data from several clinical trials are pooled into a single, larger dataset. However, pooled analyses also present the potential of salami publications, as similar variables from the same, or highly similar, set of clinical trials could be presented across several pooled analyses.
One prior investigation examined the publications associated with 42 clinical trials which examined antidepressants submitted to the Swedish drug regulatory authority [15] . The authors found 11 pooled analyses in which the trials' data were utilized; in some instances, individual trials contributed data to multiple such pooled analyses. However, their sample of pooled analyses was relatively small and the topics of the pooled analyses were not mentioned, making it difficult to know to what extent the pooled analyses contained redundant data. The present study examined the prevalence of salami publications across pooled analyses in the case of the antidepressant duloxetine for depression, focusing on studies that discussed the safety and efficacy of the drug.
Method

Search Strategy
We searched Medline and the Cochrane Registry of Controlled Clinical Trials on October 9, 2007 using the search term 'duloxetine'. Duloxetine was selected as the drug of choice because a literature search for a prior meta-analysis [16] revealed the existence of several pooled analyses regarding the drug's safety and efficacy in depression which seemed to present quite similar data. As our analysis was intended to solely investigate studies which examined the efficacy and safety of duloxetine in the treatment of depression, we excluded papers that did not focus directly on these outcomes. Our search yielded 520 articles, of which 401 were eliminated for the following reasons: studied animals (n = 49); primarily described the biological effects (i.e., pharmacokinetics or pharmacodynamics) of duloxetine (n = 44); were not relevant to depression (n = 253); were not published in English (n = 23); were case studies (n = 25) or letters to the editor (n = 7).
Analysis
Two reviewers (G.I.S., T.L.B., or D.L.S.) independently categorized each publication into one of three categories: clinical trial, pooled analysis (or post hoc analysis of a single trial), or narrative review article. All disagreements were resolved through consensus. If a publication reported data from a single study in which depressed participants received duloxetine, it was classified as a clinical trial. A placebo or active medication control was not necessary for inclusion as a clinical trial. Pooled analyses combined data from two or more clinical trials and must have reported original statistical analyses. We also categorized articles reporting post hoc analyses from a single trial as pooled analyses. Papers which discussed findings of duloxetine research but conducted no original statistical analyses were considered narrative reviews. As our interest was on the literature that primarily concerned duloxetine, we did not include papers which focused on duloxetine as but one of many treatments. For example, a meta-analysis that examined outcomes of all second-generation antidepressants was not included, as its overall focus was on second-generation antidepressants as a whole, not duloxetine in isolation [17] . However, papers which focused on how duloxetine compared to other treatments were included. In each pooled analysis, we examined which clinical trials contributed data for analysis. Whether each publication had at least one author who was an employee of Eli Lilly (manufacturer of duloxetine) was also tabulated.
Labeling an individual paper as a salami publication is at least somewhat subjective in several aspects. For example, if 7 pooled analyses exist regarding a drug's safety for a particular condition, then various reviewers may differ regarding whether each slice of data merited publication as a stand-alone paper. One reviewer may conclude that the data contained across the 7 publications could have been more efficiently presented in 1 or 2 publications, but another reviewer may differ entirely in his or her assessment. Given the inexact nature of assessing overlapping publications, we opted not to label each included pooled analysis as either a salami publication or as sufficiently original. Rather, we examined the general conclusions of each pooled analysis and noted which underlying clinical trials contributed data to each pooled publication. We then noted areas in which data and conclusions appeared to be redundant.
Results
We found 30 papers which utilized duloxetine in a clinical trial for the treatment of major depression. In addition, our literature search netted 43 pooled analyses (2 of which were post hoc analyses of a single trial) and 46 review articles. Of the clinical trials, 25 (83%) had at least one author who was employed by Eli Lilly. Of the 43 pooled analyses, 38 (88%) had at least 1 Eli Lilly-affiliated author, while 8 (17%) of the narrative review articles had at least one Eli Lilly author.
While reviewing the clinical trials, we found one instance of duplicate publication. A trial compared the outcomes of untreated depressed patients who initiated duloxetine to depressed patients who switched from their current antidepressant to duloxetine. One paper reported outcomes after 8 weeks of the 12-week trial [18] , while a second paper reported outcomes at study endpoint without referencing the other publication [19] . Table 1 shows the authors' conclusions from each pooled analysis along with the topic of analysis. Several pooled analyses authored by Eli Lilly scientists appeared to demonstrate 'salami slicing'. For example, one study [20] compared the safety and efficacy of duloxetine in the treatment of African-Americans to Caucasians. Using data from the same underlying clinical trials, another publication compared duloxetine's efficacy and safety between Hispanics and Caucasians [21] . In both cases, the authors concluded that the racial groups did not differ in a meaningful way in their response to duloxetine. Another pooled analysis compared males and females in terms of safety outcomes [22] , and another analysis based on the same underlying patients [23] compared genders in terms of efficacy, with neither analysis finding any notable differences along gender lines. One pooled analysis examined the cardiovascular effects of duloxetine in depressed patients [24] while another such analysis reported on the cardiovascular profile of the drug across various conditions [25] ; both concluded that the drug possesses a benign cardiovascular safety profile. Other safety or tolerability concerns were examined in several pooled analyses, many of which were based on a very similar set of underlying trials: body weight [26] ; suicidal behaviors and ideation [27] ; discontinuation symptoms [28] ; treatment-emergent hypomania [29] ; sexual functioning [30] ; urinary side effects [31] , and nausea [32] . Other pooled analyses provided analyses of duloxetine's safety and efficacy in patients aged 55 and over [33] and women aged 40-55 [34] ; neither analysis concluded that age moderated the drug's efficacy. Several pooled analyses also examined other factors that may moderate the impact of duloxetine: dose-response relationship [35] [36] [37] ; level of depression severity as a moderator of efficacy [38, 39] ; characteristics of depressive episode [40] , and the presence of melancholic features [41] . These analyses concluded that none of the aforementioned traits, with the exception of drug dosage, influenced patient outcome. Other pooled datasets yielded reports of duloxetine's effects in: treating milder depression [42] ; treating depression using number needed to treat as the outcome variable [43] ; time course to improvement [44] ; onset of action [45] , and treating depression with comorbid anxiety symptoms [46] . The analyses examining time course to improvement and onset of action were based on the same 2 underlying clinical trials. In addition, 6 pooled analyses reported analyses based solely on data from 2 clinical trials. Double-blind clinical trials were easily the most commonly included sources of data in pooled analyses. Table 2 displays the number of occasions in which the 8 most frequently cited clinical trials, all of which were double-blind, were included as part of a pooled analysis. Six trials were included in 20 or more pooled analyses. 'Abrupt discontinuation of duloxetine is associated with a [discontinuation-emergent adverse event] profile similar to that seen with other selective serotonin reuptake inhibitor (SSRI) and selective serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants.' (p. 207) 'Overall, changes on all outcome measures and response and remission rates were significantly greater in duloxetine-treated patients than in placebo-treated patients. Furthermore, the effect of duloxetine was similar across all episode characteristic groups (first/subsequent episode, short/ medium/long episode duration).' (p. 285) Perahia et al. [42] Treatment of milder major depression Yes [51, 53] 'In conclusion, duloxetine 60 mg/day is effective and well-tolerated in milder MDD.' (p. 613) Perahia et al. [72] Depression: risk-benefit profile compared to venlafaxine
Yes
Two trials published after end of our search period 'Duloxetine 60 mg/day and venlafaxine XR 150 mg/day have similar benefit-risk profiles on the basis of a comparison utilizing [global benefitrisk assessment].' (p. 2) Pritchett et al. [36] Using effect size to determine optimal duloxetine dose Yes [50, 51, 53, 56, 57, 81] 'The effect size analyses demonstrate that duloxetine 40 mg has minimum efficacy, and that duloxetine 60-120 mg/day is effective in the treatment of patients with MDD. An initial dose less than 60 mg/day might provide better tolerability for some patients diagnosed with MDD.' (p. 42) Raskin et al. [73] Post-hoc analysis of single trial Yes [69] 'Duloxetine demonstrated a faster time to antidepressant response and improvement in self-reported pain as compared with placebo.' (p. 309) Shelton et al. [39] Level of depression severity as moderator of efficacy Yes [51, 53, 69, 74] 'Regardless of baseline MDD severity, duloxetine at one dose (60 mg/day) produced a significant improvement compared with placebo on the core emotional symptoms of MDD.' (p. 1345) Shelton et al. [38] Level of depression severity as moderator of efficacy Yes [50, 51, 53, 54, 56, 57, 69, 80, 81] 'Duloxetine demonstrated superior efficacy in the treatment of major depressive disorder, when compared with placebo, regardless of baseline severity of depressive symptoms, although effect sizes were largest in the most severely depressed patients.' (p. 348) Stewart et al. [22] Male vs. female: safety Yes [50-54, 80, 81] 'No evidence of clinically meaningful sex differences in the safety and tolerability of duloxetine were uncovered.' (p. 183) Thase et al. [24] Cardiovascular profile Yes [50, 51, 53, 54, 56, 57, 75, 80, 81] 'These data demonstrate that duloxetine has modest effects on heart rate and BP and no clinically meaningful effect on electrocardiogram profiles in a relatively healthy cohort of clinical trial patients.' (p. 132) Van Baardewijk et al. [76] [50-54, 56, 57, 69, 74, 80, 81] 'Overall, the findings presented here support our conclusions that use of duloxetine does not appear to be associated with significant cardiovascular risks in patients with conditions for which the drug has been approved or studied.' (p. 438) Wise et al. [26] Effect on body weight Yes [50, 51, 53, 54, 56, 57, [78] [79] [80] [81] 'Duloxetine-treated patients experienced weight loss after short-term treatment, followed by modest weight gain on longer-term treatment. The size of the weight changes observed suggests that the antidepressant duloxetine has minimal effects on weight for the majority of patients.' (p. 269) 
Discussion
Our findings suggest that many pooled analyses regarding the efficacy and safety of duloxetine have substantial redundancy. In many instances, it was difficult to ascertain how such salami publications were making substantial contributions to the scientific literature. Several clinical trials were included in over 20 pooled analyses.
We do not claim that the scientific questions examined in the pooled analyses lacked legitimate scientific importance. For example, the potential interaction of gender and race with treatment response is certainly a topic of interest. However, given that Latinos, Blacks, and Whites all tended to respond similarly to duloxetine and that gender also did not moderate outcome, it seems that such data could easily have been presented in a single publication rather than in 3 published pooled analyses. Likewise, data on safety outcomes were sliced into several pieces. It is unclear how an individual publication is needed to report data separately for safety outcomes such as nausea, sexual side effects, urinary side effects, and several others. Multiple publications based on similar data which conclude that duloxetine is effective for mild depression, melancholic depression, and across differing lengths of depressive episodes likewise seem redundant. A much smaller number of publications could likely have communicated such data just as clearly. Further, the sample size of some pooled analyses was rather small; 6 pooled analyses included only data from 2 clinical trials. It is likely that exceedingly few meta-analyses have been published based on only 2 trials, raising the question of why pooled analyses based on only 2 trials warrant publication in the absence of novel scientific data.
A limitation of the current investigation is that the inappropriateness of 'salami slicing' is not universally agreed upon. What may be considered redundant information by some may be considered an important scientific contribution by others. Thus, we acknowledge that different evaluators may draw different conclusions regarding whether these publications were appropriate. However, we believe that publishing similar outcomes from the same dataset of publications on several occasions better serves the curricula vitae of researchers and, potentially, goals of drug marketers, than it does science and patient care.
Outside of Melander et al. [15] , we are aware of no other investigation which has examined the prevalence of redundant pooled analyses. We only included publications on a single drug and focused on only the literature related to one of its multiple indications. It is certainly possible that pooled analyses regarding duloxetine are not representative of the broader scientific literature. Indeed, given our limited focus, it is likely inappropriate to generalize that pooled analyses containing redundant data are widely spread in the psychiatric or wider medical literature. We have simply demonstrated that in the instance of duloxetine in the treatment of depression, 'salami slicing' appears to have taken place with substantial frequency via pooled analyses.
Writings from the drug industry indicate that medical journal publications, rather than just communicating scientific findings, are an important part of the drug marketing process. As written in a medical marketing trade publication, 'the goal of strategic publication planning is to accelerate the adoption of a new chemical entity and, by doing so, accelerate uptake after it enters the market' [ 47 , p. 41] . The same author noted that a good strategic publication plan supports a product's 'selling platform' [ 47 , p. 41] . Documents from Pfizer and Eli Lilly indicate similar views, that journal publications are linked to product sales [7, 8] .
Journal editors, peer reviewers, and researchers should be aware that salami publication wastes valuable resources of editors, reviewers, and journals [1] [2] [3] [4] [5] [6] . Further, salami publications may be more representative of propaganda than of actual contributions to science [48] . The fact that such redundant publications have appeared in a wide variety of medical journals raises questions about the quality of peer review and what passes for 'original' science. A recent editorial raised concerns that the medi- 18 Perahia et al. [56] 17
